[
  {
    "ts": null,
    "headline": "Viridian Therapeutics: Cautious Optimism As Key Milestones Approach (Rating Downgrade)",
    "summary": "Viridian Therapeutics has surged on thyroid eye disease wins, big growth forecasts, and improved funding ahead of the FDA rollout. Read the VRDN stock update.",
    "url": "https://finnhub.io/api/news?id=321c1dcae94223a4da773a034661eb2dea6768a882b5d80b27b0395dd7703ee4",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769436326,
      "headline": "Viridian Therapeutics: Cautious Optimism As Key Milestones Approach (Rating Downgrade)",
      "id": 138264105,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2016447711/image_2016447711.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Viridian Therapeutics has surged on thyroid eye disease wins, big growth forecasts, and improved funding ahead of the FDA rollout. Read the VRDN stock update.",
      "url": "https://finnhub.io/api/news?id=321c1dcae94223a4da773a034661eb2dea6768a882b5d80b27b0395dd7703ee4"
    }
  },
  {
    "ts": null,
    "headline": "Amgen's (NASDAQ:AMGN) 11% CAGR outpaced the company's earnings growth over the same five-year period",
    "summary": "If you buy and hold a stock for many years, you'd hope to be making a profit. But more than that, you probably want to...",
    "url": "https://finnhub.io/api/news?id=0e269c7901eed9bb09683e38eb13be6990ff144369465d7e606b53002a9df75b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769428813,
      "headline": "Amgen's (NASDAQ:AMGN) 11% CAGR outpaced the company's earnings growth over the same five-year period",
      "id": 138261277,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "If you buy and hold a stock for many years, you'd hope to be making a profit. But more than that, you probably want to...",
      "url": "https://finnhub.io/api/news?id=0e269c7901eed9bb09683e38eb13be6990ff144369465d7e606b53002a9df75b"
    }
  },
  {
    "ts": null,
    "headline": "Q3 Rundown: Amgen (NASDAQ:AMGN) Vs Other Therapeutics Stocks",
    "summary": "As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Amgen (NASDAQ:AMGN) and its peers.",
    "url": "https://finnhub.io/api/news?id=f8ea5d8c6c21d2ee50cd09a0c1aa88f6a1170df026674402da797d8236ad376f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769398274,
      "headline": "Q3 Rundown: Amgen (NASDAQ:AMGN) Vs Other Therapeutics Stocks",
      "id": 138260421,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Amgen (NASDAQ:AMGN) and its peers.",
      "url": "https://finnhub.io/api/news?id=f8ea5d8c6c21d2ee50cd09a0c1aa88f6a1170df026674402da797d8236ad376f"
    }
  }
]